<DOC>
	<DOCNO>NCT00631488</DOCNO>
	<brief_summary>This study test effectiveness safety treatment MK-0893 combination drug commonly use treat type 2 diabetes duration 13 week .</brief_summary>
	<brief_title>A Study Test Effectiveness Safety MK0893 Combination With Other Drugs Used Treat Type 2 Diabetes ( 0893-015 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Participants Type 2 Diabetes Mellitus , suboptimal glucose control , either AHA ( antihyperglycemic agent ) therapy monotherapy lowdose combination therapy Participants history Type 1 Diabetes Mellitus Participants take insulin thiazolidinediones ( TZDs : peroxisome proliferatoractivated receptor [ PPAR ] gamma agonist ) Participants contraindication metformin sitagliptin</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>